Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Cantor Fitzgerald
Julphar
Daiichi Sankyo
Express Scripts
US Army
Colorcon
QuintilesIMS
Teva

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,660,726

« Back to Dashboard

Which drugs does patent 6,660,726 protect, and when does it expire?

Patent 6,660,726 protects ENJUVIA and is included in one NDA.

This patent has six patent family members in six countries.
Summary for Patent: 6,660,726
Title: Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
Abstract:Novel estrogenic compounds of Formula I are provided. ##STR1## wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R.sub.1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R.sub.1 does not exist; R.sub.2 is lower alkyl; R.sub.3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R.sub.4 through R.sub.13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R.sub.14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R.sub.1 is hydroxy, the hydroxy or ester substituent may have either an .alpha. or a .beta. orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
Inventor(s): Hill; Edward N. (Wilmington, NC), Sancilio; Frederick D. (Wilmington, NC), Whittle; Robert R. (Wilmington, NC)
Assignee: Endeavor Pharmaceuticals (Wilmington, NC)
Application Number:09/800,614
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,660,726

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Teva Branded Pharm ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-001 Dec 20, 2004 DISCN No No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE ➤ Sign Up
Teva Branded Pharm ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-001 Dec 20, 2004 DISCN No No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE ➤ Sign Up
Teva Branded Pharm ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-002 Dec 20, 2004 DISCN No No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE ➤ Sign Up
Teva Branded Pharm ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-002 Dec 20, 2004 DISCN No No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,660,726

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,227,454 Estrogenic compounds, pharmaceutical compositions and formulations comprising the same ➤ Sign Up
7,179,799 (3) and (6) substituted estrogenic compounds ➤ Sign Up
6,250,127 Heat-dissipating aluminum silicon carbide composite manufacturing method ➤ Sign Up
7,989,436 Estrogenic compounds and pharmaceutical formulations comprising the same ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Argus Health
Colorcon
AstraZeneca
Fuji
Julphar
Cantor Fitzgerald
Accenture
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.